Search Results for 'survival trial'
survival trial published presentations and documents on DocSlides.
Survival Analysis for Randomized Clinical Trials
by celsa-spraggs
Ziad. . Taib. March . 3, 2014. I The log-rank te...
DCVax®-L 020221 Phase 3 Clinical Trial
by cappi
Dendritic Cell Therapy for Brain Cancer. Where Are...
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
by maniakti
Richard S. Finn, MD. Professor of Clinical Medicin...
A Phase III Randomized Controlled Trial of Secondary Cytoreductive Surgery followed by Platinum-Bas
by catherine
A NRG Oncology-Gynecologic Oncology Group Study. R...
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
by naomi
David Morgan (King’s College, London / Consultan...
Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial
by ayaan
Progression-Free Survival of Isa-. KRd. in High-R...
Molecular Lessons Learnt from Clinical Trials in the Last Decade
by altigan
Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...
Blinded Sample Size Re-estimation in a Phase III Study Inve
by luanne-stotts
David Morgan (King’s College, London / Consulta...
Cardiogenic Shock Where Do We Go After The SHOCK Trial
by mia
William W. O’Neill, MD. Henry Ford Health System...
Diagnosis and Initial Therapy of MM
by tremblay
Myeloma Symposium 9/29/2018. Aric Hall, MD – Ass...
Disparities in Prostate Cancer Outcomes: Race, Access, and Ancestry
by Soulmate
Andrew J Armstrong MD . ScM. FACP. National Allia...
A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy
by bikersjoker
patients with . advanced breast . cancer and a ger...
Mr Eric Lim MB ChB, MSc (Biostatistics), MD, FRCS (C-
by likets
Th. ). Consultant Thoracic Surgeon. Academic Divis...
Andrew H. Ko, MD University of California San Francisco
by test
Gastrointestinal Oncology Program. Treatment of m...
Oncology Clinical Trials in the
by sherrill-nordquist
Presence of Non-Proportional . Hazards. The Duke-...
The Nurse View: Management of Pancreatic Cancer
by myesha-ticknor
Activity Goals. Introduction. Introduction (cont)...
Transforming treatment and improving survival for
by olivia-moreira
ovarian cancer patients. Laura Shawver, PhD. Foun...
Best Practices in Nursing Management of EGFR Inhibitor Rash
by olivia-moreira
Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Pr...
No Does the New EPOC trial eliminate anti-EGFR antibodies a
by sherrill-nordquist
The New EPOC Study. Randomi. ze. Surgery. Oxalipl...
Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent t
by sherrill-nordquist
Yes . Deborah . Schrag. , MD, MPH. No. John L. Ma...
Hazard ratios are commonly used when presenting results in clinical trials involving survival data and allow hypothesis testing
by natalia-silvester
They should not be considered the same as relativ...